International Consensus Guidance Provides Framework for Monitoring Patients With Type 1 Diabetes

Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, recently announced the first international consensus guidance, “Consensus Guidance for Monitoring Persons With Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes,” for monitoring people who test positive for 1 or more islet autoantibodies associated with T1D. The guidance was presented recently at the American Diabetes Association’s 84th Scientific Sessions.

DocWire News spoke with Anastasia Albanese-O’Neill, AVP of Community Screening and Clinical Trial Education at Breakthrough T1D, who led the process of developing the consensus guidance, which addresses a significant unmet need in the treatment of T1D—the necessity for more screening and monitoring—which is not currently commonplace and could completely change the course for many people who will develop the chronic disease.